期刊文献+

依非韦伦关键中间体的合成 被引量:1

Synthesis of the Key Intermediate of Efavirenz
原文传递
导出
摘要 报道了依非韦伦关键中间体(S)-1-(2-氨基-5-氯苯基)-1-三氟甲基-3-环丙基-2-丙炔-1-醇(1)的合成。对氯苯胺(2)与特戊酰氯反应得N-(4-氯苯基)-2,2-二甲基丙酰胺(4),4与三氟乙酸酐在三氯化铝作用下经傅-克酰基化反应后,酸性水解得4-氯-2-三氟乙酰基苯胺盐酸盐(5),革除了危险试剂正丁基锂的使用。化合物5经碱化得4-氯-2-三氟乙酰基苯胺(6)。化合物6在氯化锌和(1R,2S)-1-苯基-2-(1-吡咯烷基)-1-丙醇(7)形成的催化体系中与少量纯品1和环丙乙炔氯化镁经不对称自催化反应制得1。该步反应用氯化锌代替价昂且危险的二乙基锌;收率由79%提高至85.6%;配体7可被有效回收,回收率98%,降低了成本。优化后的工艺反应条件温和,各步反应收率优良,总收率69.5%(以2计)。 The key intermediate of efavirenz: (S) -1- (2-amino-5-chlorophenyl) - 1-trifluoromethyl-3-cyclopropyl- 2-propyne-l-ol (1) was prepared, p-Chloroaniline (2) reacted with pivaloyl chloride to give N-(4-chlorophenyl)-2,2- dimethylpropanamide (4). After a Friedel-Crafts acylation of compound 4 catalyzed by aluminum trichloride, and a hydrolysis under acidic conditions, 4-chloro-2-(trifluoroacetyl)aniline hydrochloride (5) was obtained. In this step, the hazardous reagent n-butyllithium was abolished. Compound 5 was basified to afford 4-chloro-2-(trifluoroacetyl)aniline (6). Then compound 6 reacted with chloromagnesium cyclopropylacetylide under the catalytic system formed by zinc chloride and (1R,2S)-1-phenyl-2-(1-pyrrolidinyl)-1-propanol (7) and a small amount of purified 1 to obtain the target compound 1 by asymmetric autocatalysis with an overall yield of 69.5 % (based on 2). In the last step, zinc chloride was used instead of diethylzinc, the yield was increased from 79% to 85.6%. And ligand 7 was recovered with a recovery rate of 98 %, which could reduce the cost successfully. This improved synthetic route has mild reaction conditions and the yield of each step was excellent.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2018年第1期49-52,共4页 Chinese Journal of Pharmaceuticals
关键词 依非韦伦 关键中间体 不对称自催化 合成 efavirenz key intermediate asymmetric autocatalysis synthesis
  • 相关文献

参考文献3

二级参考文献48

  • 1Richman D,Bozette S,Morton S,et al.The prevalence of antiretroviral drug resistance in the US[A].Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy[C].Chicago,December 16-19,2001.Washington,D.C.:American Society for Microbiology,2001.
  • 2Little SJ,Holte S,Routy J-P,et al.Antiretroviral-drug resistance among patients recently infected with HIV[J].N Engl J Med,2002,347:385-394.
  • 3Grant RM,Hecht FM,Warmerdam M,et al.Time trends in primary HIV-1 drug resistance among recently infected persons[J].JAMA,2002,288:181-188.
  • 4Yeni PG,Hammer SM,Carpenter CC,et al.Antiretroviral treatment for adult HIV infection in 2002:updated recommendations of the International AIDS Society-USA Panel[J].JAMA,2002,288:222-235.
  • 5Shet A,Markowitz M.Transmitted multidrug resistant HIV-1:new and investigational therapeutic approaches[J].Curr Opin Investig Drugs,2006,7(8):709-720.
  • 6Fox J,Dustan S,McClure M,et al.transmitted drug-resistant HIV-1 in primary HIV-1 infection:incidence,evolution and impact on response to antiretroviral therapy[J].HIV Med,2006;7:477-483.
  • 7Vergne L,Diagbouga S,Kouanfack C,et al.HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon[J].Antivir Ther,2006,11(5):575-579.
  • 8Ross LL,Dretler R,Gerondelis P,et al.A rare HIV reverse transcriptase mutation,K65N,confers reduced susceptibility to tenofovir,lamivudine and didanosine[J].AIDS,2006,20(5):787-789.
  • 9Gianotti N,Galli L,Boeri E,et al.The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients[J].J Acquir Immune Defic Syndr,2006,41(4):447-452.
  • 10Brenner BG,Oliveira M,Doualla-Bell F,et al.HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture[J].AIDS,2006,20(9):F9-13.

共引文献32

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部